Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

KT-253, a Highly Potent and Selective MDM2 Protein Degrader, Eliminates Malignant Myelofibrosis Stem/Progenitor Cells

Min Lu, Lijuan Xia, Yogesh Chutake, Joyoti Dey, Ronald Hoffman

Blood (2024) 144 (Supplement 1): 3588.

https://doi.org/10.1182/blood-2024-210354

Published: 2024

Journal Articles

TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2 V617F Mutant Mice

Maayan Levy, Huihui Li, Andrew Dunbar, Zixing Huang, Young Park, Min Lu, Pinanong Na Phattalung, Marina Planoutene, Carla Casu, Stefano Rivella, Shuling Guo, Ross L Levine, Ronald Hoffman, Yelena Ginzburg

Blood (2024) 144 (Supplement 1): 8.

https://doi.org/10.1182/blood-2024-203806

Published: 2024

Journal Articles

Selinexor Depletes Ruxolitinib Refractory Myelofibrosis Hematopoietic Stem Cells By Inducing Apoptosis and Blunting the Pro-Inflammatory Milieu

Min Lu, MD Babu Mia, Lijuan Xia, Andrea Ellero, Christopher J. Walker, Ronald Hoffman

Blood (2024) 144 (Supplement 1): 1377.

https://doi.org/10.1182/blood-2024-205114

Published: 2024

Journal Articles

Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells

Cara Clementelli, MD Babu Mia, Sarah Haines, Christoph Schaniel, Malgorzata Olszewska, Joann Arandela, Sebastian Elghaity-beckley, Sophie Klingborg, Zinedine Hoque, Min Lu, Eirini Papapetrou, Ronald Hoffman, Bridget Kelly Marcellino

Blood (2024) 144 (Supplement 1): 873.

https://doi.org/10.1182/blood-2024-204136

Published: 2024

Journal Articles

Use of Combination Therapies Including the XPO1 Inhibitor Selinexor in Is a Potential Effective Therapeutic Strategy to Treat Myelofibrosis Patients

Min Lu, Lijuan Xia, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 1792.

https://doi.org/10.1182/blood-2023-186674

Published: 2023

Journal Articles

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

Blood (2023) 141 (20): 2508–2519.

https://doi.org/10.1182/blood.2022015418

Published: 2023

Includes: Supplemental data

Journal Articles

Dual Targeting of HDM2 and PPM1D As a Novel Therapeutic Approach for Myelofibrosis

Bridget K Marcellino, Cara Clementelli, Kristin Beaumont, Christoph Schaniel, Min Lu, Karie Chen, Adena Russel, Ayman Mohammad, Daniel I Nathan, Jake Aronin, Alan H. Shih, Robert Sebra, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 797–798.

https://doi.org/10.1182/blood-2022-170232

Published: 2022

Journal Articles

Co-Cultivation of MF CD34+ Cells with Microenvironmental Cells Has a Profound Effect on MF Hematopoiesis and Responses to Drug Therapy

Min Lu, Christoph Schaniel, Jeff Vierstra, Lijuan Xia, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 8625–8626.

https://doi.org/10.1182/blood-2022-170704

Published: 2022

Journal Articles

Pharmacological Disruption of the Interplay between HDM2-p53 and NFκB Depletes Myelofibrosis Progenitor/Stem Cells and Dampens the Accompanying Inflammatory Milieu

Min Lu, Lijuan Xia, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 3069–3070.

https://doi.org/10.1182/blood-2022-169781

Published: 2022

Journal Articles

Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms

Andrew Dunbar, MD, Min Lu, PhDMD, Mirko Farina, MD, Young Park, BS, Julie Yang, PhD, Dongjoo Kim, PhD, Abdul Karzai, BS, Mohamed E Salama, MD, Jenna Snyder, BS, Aishwarya Krishnan, BS, Richard P. Koche, PhD, Rong Fan, PhD, Ross L. Levine, MD, Ronald Hoffman, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-138843

Published: 2020

Journal Articles

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

Bridget Marcellino, MD PhD, Bruno Cassinat, PharmD, PhD, Noushin Farnoud, PhD, Min Lu, PhD, Emmanuelle Verger, PhD, Erin McGovern, BA, Minal A Patel, MPH, Heidi E. Kosiorek, MS, Meenakshi Mehrotra, PhD, Jane Houldsworth, PhD, Amylou C. Dueck, PhD, Michael Rossi, PhD, Jean-Jacques Kiladjian, MD PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 838.

https://doi.org/10.1182/blood-2019-128342

Published: 2019

Journal Articles

A Novel Combination of Drugs Which Target Both the Intrinsic and Extrinsic Apoptotic Pathways to Eliminate Myelofibrosis CD34+ Cells

Min Lu, PhD, Lijuan Xia, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4201.

https://doi.org/10.1182/blood-2019-129017

Published: 2019

Journal Articles

Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

Bridget Marcellino, MD PhD, Joseph Tripodi, Michal Bar-Natan, MD, Harry Fruchtman, Noushin Farnoud, PhD, Min Lu, PhD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Vesna Najfeld, PhD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4207.

https://doi.org/10.1182/blood-2019-129565

Published: 2019

Journal Articles

Oral idasanutlin in patients with polycythemia vera

John Mascarenhas, Min Lu, Heidi Kosiorek, Elizabeth Virtgaym, Lijuan Xia, Lonette Sandy, Ruben Mesa, Bruce Petersen, Noushin Farnoud, Vesna Najfeld, Raajit Rampal, Amylou Dueck, Ronald Hoffman

Blood (2019) 134 (6): 525–533.

https://doi.org/10.1182/blood.2018893545

Published: 2019

Includes: Supplemental data

Journal Articles

Enriched Populations of Human Megakaryocytic Cells Affect the Behavior of Myelofibrosis CD34+ Cells As Well As Cells Belonging to the MF Supportive Microenvironment

Min Lu, PhD MD, Lijuan Xia, Mohamed E. Salama, MD, Ronald Hoffman, MD

Blood (2018) 132 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2018-99-117062

Published: 2018

Journal Articles

Advanced Forms of the Myeloproliferative Neoplasms Are Associated with Chromosomal Abnormalities Involving 1q and 12q: Implicating MDM2 and MDM4 in Disease Progression

Bridget Marcellino, MD PhD, Joseph Tripodi, Min Lu, PhDMD, Heidi Kosiorek, MS, John Mascarenhas, MD, Raajit K. Rampal, MD PhD, Amylou Constance Dueck, PhD, Ronald Hoffman, MD, Vesna Najfeld, PhD

Blood (2017) 130 (Supplement 1): 204.

https://doi.org/10.1182/blood.V130.Suppl_1.204.204

Published: 2017

Journal Articles

Combination Treatment with an MDM2 Antagonist and a BET Inhibitor Targets Both Myelofibrosis Hematopoietic Stem/ Progenitor Cells and Their Tumor Promoting Microenvironment

Min Lu, PhDMD, Lijuan Xia, Mohamed E. Salama, MD, Ronald Hoffman, MD

Blood (2017) 130 (Supplement 1): 4225.

https://doi.org/10.1182/blood.V130.Suppl_1.4225.4225

Published: 2017

Journal Articles

Open Label Phase I Study of Single Agent Oral RG7388 (idasanutlin) in Patients with Polycythemia Vera and Essential Thrombocythemia

John Mascarenhas, MD, Min Lu, PhDMD, Elizabeth Virtgaym, Heidi Kosiorek, MS, Marina Stal, Lonette Sandy, Alicia Orellana, MD MPH, Lijuan Xia, Marina Kremyanskaya, MD PhD, Bruce Petersen, MD, Amylou Dueck, PhD, Ronald Hoffman, MD

Blood (2017) 130 (Supplement 1): 254.

https://doi.org/10.1182/blood.V130.Suppl_1.254.254

Published: 2017

Journal Articles

Splenic Micro Environmental Cells from Patients with Myelofibrosis Elaborate a Cascade of Cytokines and Serve As a Niche for Malignant Hematopoiesis

Min Lu, PhD MD, Lijuan Xia, Mohamed E Salama, MD, Ronald Hoffman, MD

Blood (2016) 128 (22): 953.

https://doi.org/10.1182/blood.V128.22.953.953

Published: 2016

Journal Articles

Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells

Min Lu, Lijuan Xia, Yen-Chun Liu, Tsivia Hochman, Laetizia Bizzari, Daniel Aruch, Jane Lew, Rona Weinberg, Judith D. Goldberg, Ronald Hoffman

Blood (2015) 126 (8): 972–982.

https://doi.org/10.1182/blood-2014-12-618595

Published: 2015

Includes: Supplemental data

NARROW

KT-253, a Highly Potent and Selective MDM2 Protein Degrader, Eliminates Malignant Myelofibrosis Stem/Progenitor Cells

TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2 V617F Mutant Mice

Selinexor Depletes Ruxolitinib Refractory Myelofibrosis Hematopoietic Stem Cells By Inducing Apoptosis and Blunting the Pro-Inflammatory Milieu

Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells

Use of Combination Therapies Including the XPO1 Inhibitor Selinexor in Is a Potential Effective Therapeutic Strategy to Treat Myelofibrosis Patients

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

Dual Targeting of HDM2 and PPM1D As a Novel Therapeutic Approach for Myelofibrosis

Co-Cultivation of MF CD34+ Cells with Microenvironmental Cells Has a Profound Effect on MF Hematopoiesis and Responses to Drug Therapy

Pharmacological Disruption of the Interplay between HDM2-p53 and NFκB Depletes Myelofibrosis Progenitor/Stem Cells and Dampens the Accompanying Inflammatory Milieu

Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

A Novel Combination of Drugs Which Target Both the Intrinsic and Extrinsic Apoptotic Pathways to Eliminate Myelofibrosis CD34+ Cells

Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

Oral idasanutlin in patients with polycythemia vera

Enriched Populations of Human Megakaryocytic Cells Affect the Behavior of Myelofibrosis CD34+ Cells As Well As Cells Belonging to the MF Supportive Microenvironment

Advanced Forms of the Myeloproliferative Neoplasms Are Associated with Chromosomal Abnormalities Involving 1q and 12q: Implicating MDM2 and MDM4 in Disease Progression

Combination Treatment with an MDM2 Antagonist and a BET Inhibitor Targets Both Myelofibrosis Hematopoietic Stem/ Progenitor Cells and Their Tumor Promoting Microenvironment

Open Label Phase I Study of Single Agent Oral RG7388 (idasanutlin) in Patients with Polycythemia Vera and Essential Thrombocythemia

Splenic Micro Environmental Cells from Patients with Myelofibrosis Elaborate a Cascade of Cytokines and Serve As a Niche for Malignant Hematopoiesis

Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only